Assembly Biosciences Inc (ASMB) Quote

ASMB: effective Feb. 12,2024 a one for 12 reverse split:

https://hedgefollow.com/upcoming-stock-splits.php

$ 1 - $ 1,20 NEXT WEEK???????????????

100 %!!!!!!!!!!!!! The stock would have to rise by 100 % just to reach the cash value of the company (HAI)!!!!!!!!!!!!!!!!

GILEAD AND ASSEMBLY BIOSCIENCES = PERFECT PARTNERSHIP!!!!!!!!!!!!!!!!!!!!!!!!!!!

GOOOOOOOOOOOOO ASMB GOOOOOOOOOOOOOOOOOO!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

LET`S GO BACK TO $ 10!!!!!!!!!!!!!!!!!!!!!!!!!

Q3 earnings coming up soon.

Average trade so far today is 1.39. Seems to be consolidating nicely. Let's see what the AH game is.

probably see $1 before $5

Maybe

Anytime or soon......... whichever comes first.

Or when would u like it ???


We'll customize the timeline for you

5 when

$ASMB: Serious buy here at $1.50.......... $100Milly CASH UPFRONT

From $GILD............... and they don't show any sales here at $1.50 with a $38Milly MCap.

This is going to $5 soon enough


GO $ASMB

https://ih.advfn.com/stock-market/NASDAQ/assembly-biosciences-ASMB/stock-news/92292755/gilead-taking-stake-in-assembly-bio-under-antivira

https://finviz.com/quote.ashx?t=ASMB&ty=c&ta=1&p=d

https://dilutiontracker.com/app/search/ASMB?a=dbb88c

$ASMB easy math.... $100M upfront payment + $43M currently in cash with outstanding shares of 52.61M the current cash per share is now around $2.75 @BioStocks pic.twitter.com/kA1ucDbNeM— Antonio Costa (@ACInvestorBlog) October 17, 2023

Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases
––Partnership combines Gilead’s proven track record and mission to develop transformative therapeutics targeting serious viral diseases, with Assembly Bio’s expertise and focus on antiviral R&D to advance differentiated treatments for herpesviruses, HBV, HDV and beyond—

—Collaboration includes Assembly Bio’s current and future pipeline candidates and incorporates two Gilead herpesvirus programs—

—Assembly Bio to receive $100 million upfront payment, including equity investment, plus potential for future regulatory, commercial, opt-in and collaboration extension payments—

—Assembly Bio management to host webcast today at 8:30 a.m. ET/5:30 a.m. PT—

FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that the companies have entered into a 12-year partnership to advance the research and development of novel antiviral therapies, with an initial focus in Assembly Bio’s established areas of herpesviruses, hepatitis B virus (HBV) and hepatitis D virus (HDV).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231017843279/en/

Assembly Bio’s current portfolio of small molecule antiviral therapeutics includes both clinical and preclinical programs, including next-generation core inhibitor ABI-4334 for the treatment of HBV, long-acting helicase-primase inhibitor ABI-5366 for herpes simplex virus (HSV), an orally bioavailable HDV entry inhibitor ABI-6250, and a pan-herpes polymerase inhibitor program.

“Advancing the next wave of innovation in virology remains a core focus for Gilead as we seek to address the unmet needs of people affected by serious viral infections around the world,” said Tomas Cihlar, Senior Vice President of Virology Research, Gilead. “Collaborations and partnerships are key in the pursuit of the next wave of transformative innovations. We are excited to announce this partnership with Assembly Bio to synergize our efforts on advancing and accelerating the discovery and development of novel antiviral therapeutics.”

“We are thrilled to partner with Gilead to address significant unmet medical needs in herpesviruses, viral hepatitis and beyond,” said Jason Okazaki, chief executive officer and president of Assembly Bio. “With Gilead’s established success in developing and commercializing antiviral medicines and Assembly Bio’s advanced virology research capabilities, we believe the shared expertise and promising investigational therapies that both organizations contribute to this collaboration have the potential to deliver significant advances to patients. This transaction represents a critical step in Assembly Bio’s path to becoming a fully-integrated biotechnology company and we are eager to begin working with our new partner.”

Terms of the Partnership

Under the terms of the agreement, Assembly Bio will receive $100 million, consisting of an $84.8 million upfront payment and a $15.2 million equity investment from Gilead. Gilead’s initial equity investment at a premium represents 19.9 percent of the outstanding voting stock of Assembly Bio as of the date of closing. In addition, subject to certain conditions, Gilead has agreed to purchase up to 29.9 percent of Assembly Bio’s outstanding voting stock at a premium.

Gilead may opt-in to obtain exclusive rights for each of Assembly Bio’s current and future programs, including two preclinical programs targeting HSV and transplant-associated herpesviruses that Gilead is licensing to Assembly Bio, upon payment of an opt-in fee of at least $45 million per program after clinical proof-of-concept is achieved. If Gilead opts-in to any current or future program under the collaboration, Assembly Bio is eligible to receive up to $330 million per program in potential regulatory and commercial milestones, in addition to royalties ranging from the high single digits to high teens. During the term of the collaboration, Assembly Bio will also be eligible to receive three separate $75 million collaboration extension payments at prespecified timepoints during the collaboration term to help fund future research and development.

Following Gilead’s exercise of its option for an Assembly Bio program, Assembly Bio will have the right to opt-in to share profits and costs in the United States. For future new programs, Assembly Bio will also have an option to co-promote those products in the United States.

Assembly Bio will be primarily responsible for the research and development efforts on the collaboration programs, including the two contributed Gilead programs, prior to Gilead’s potential opt-in. Following Gilead’s opt-in, Gilead will control discovery, research, development and commercialization on the optioned program(s).

Gilead has the right to appoint two individuals to Assembly Bio’s Board of Directors.

ABI-4334, ABI-5366 and ABI-6250 are investigational and not approved anywhere globally. Their efficacy and safety have not been established. More information about clinical trials with ABI-4334 is available at www.clinicaltrials.gov.

Beginning in the first quarter of 2022, consistent with recent industry communications from the U.S. Securities and Exchange Commission (SEC), Gilead no longer excludes acquired IPR&D expenses from its non-GAAP financial measures. This transaction with Assembly Bio is expected to reduce Gilead’s GAAP and non-GAAP 2023 EPS by approximately $0.05 - $0.07.

BofA Securities, Inc. and Mizuho Securities USA LLC are acting as financial advisors to Assembly Bio. Wilson Sonsini is serving as legal counsel to Assembly Bio.

Assembly Bio Webcast

Management from Assembly Bio will be hosting an investor webcast today at 8:30 a.m. ET/5:30 a.m. PT to discuss the Gilead partnership. The live webcast will be available on the Events & Presentations page in the Investors section of Assembly Bio’s website and a replay will be accessible following the event. An accompanying slide presentation will also be available. To register for the live webcast and replay, please visit: https://investor.assemblybio.com/events-presentations.

About Assembly Biosciences

Assembly Biosciences is a biotechnology company dedicated to the development of innovative small molecule antiviral therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Led by an accomplished team of leaders in virologic drug development, Assembly Bio is committed to improving outcomes for patients struggling with the serious, chronic impacts of herpesvirus, hepatitis B virus (HBV) and hepatitis delta virus (HDV) infections. For more information, visit Assemblybio.com.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

Assembly Biosciences Forward-Looking Statements

The information in this press release contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to materially differ. These risks and uncertainties include: Assembly Bio’s ability to realize the potential benefits of its collaboration with Gilead, including all financial aspects of the collaboration and equity investments; Assembly Bio’s ability to initiate and complete clinical studies involving its therapeutic product candidates, including studies contemplated by Assembly Bio’s collaboration with Gilead, in the currently anticipated timeframes or at all; the occurrence of any event, change or other circumstance that could give rise to the termination of Assembly Bio’s collaboration with Gilead; safety and efficacy data from clinical or nonclinical studies may not warrant further development of Assembly Bio’s product candidates; clinical and nonclinical data presented at conferences may not differentiate Assembly Bio’s product candidates from other companies’ candidates; results of nonclinical studies may not be representative of disease behavior in a clinical setting and may not be predictive of the outcomes of clinical studies; and other risks identified from time to time in Assembly Bio’s reports filed with the U.S. Securities and Exchange Commission (the SEC). You are urged to consider statements that include the words may, will, would, could, should, might, believes, hopes, estimates, projects, potential, expects, plans, anticipates, intends, continues, forecast, designed, goal or the negative of those words or other comparable words to be uncertain and forward-looking. Assembly Bio intends such forward-looking statements to be covered by the safe harbor provisions contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. More information about Assembly Bio’s risks and uncertainties are more fully detailed under the heading “Risk Factors” in Assembly Bio’s filings with the SEC, including its most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Except as required by law,

ASMB’s EASL lineup:

https://www.globenewswire.com/news-release/2023/06/21/2691964/16259/en/Assembly-Biosciences-Presents-New-Data-Highlighting-Entry-Inhibitor-and-Core-Inhibitor-Programs-at-EASL-s-International-Liver-Congress-2023.html

ASMB 1Q23 results—3/31/23 cash=$73M, down from $92M at 12/31/22:

https://finance.yahoo.com/news/assembly-biosciences-reports-first-quarter-200500203.html

No CC.

ASBM abandons HBV arena, for all practical purposes:

https://finance.yahoo.com/news/assembly-biosciences-announces-additional-promising-120000883.html

No further internal development will be done on ABI-4344, ASMB’s fourth(!) HBV core inhibitor. ASMB dumped its third HBV core inhibitor, ABI-H3733, a few weeks ago and has yet to do anything right in HBV (see #msg-171513883 and the embedded links there).

According to today’s PR, ASMB’s clinical focus will now be its herpes and HDV programs.

ASBM 4Q22 results—12/31/22 cash=$92M—(down_from $109M @9/30/22):

https://finance.yahoo.com/news/assembly-biosciences-provides-core-inhibitor-200500620.html

No CC.

ASMB halts development of ABI-H3733, an HBV core inhibitor:

https://finance.yahoo.com/news/assembly-biosciences-provides-core-inhibitor-200500620.html

This is the third HBV core inhibitor that ASMB has discontinued, but it’s hardly a surprising development. ASMB has yet to get anything right in HBV—please see #msg-167605073, #msg-168960516, and #msg-169454462 for details.

ASMB—(+14%)—reports_interim phase1/1b data_for HBV core inhibitors:

https://finance.yahoo.com/news/assembly-biosciences-announces-promising-interim-130000947.html

ASMB 3Q22 results—9/30/22 cash=$109M:

https://finance.yahoo.com/news/assembly-biosciences-reports-third-quarter-210500361.html

No CC.

ASMB CEO retires:

https://www.globenewswire.com/news-release/2022/10/05/2529047/16259/en/Assembly-Bio-Announces-Retirement-of-John-G-McHutchison-AO-MD-as-CEO-and-Appoints-Current-President-and-COO-Jason-A-Okazaki-as-Successor.html

The company’s long string of clinical mishaps may have something to do with this decision (#msg-169454462, #msg-167605073).

ASMB 2Q22 results—6/30/22_cash=$128.6B (down from $146.5M at 3/31/22):

https://finance.yahoo.com/news/assembly-biosciences-reports-second-quarter-200500797.html

No CC.

ASMB discontinues Vebicorvir for HBV, a smart decision that should’ve been made quite a while ago:

https://www.globenewswire.com/news-release/2022/07/20/2483157/16259/en/Assembly-Biosciences-Announces-Program-Reprioritization-and-Organizational-Update.html Assembly Biosciences will discontinue clinical development of its first-generation investigational core inhibitor, VBR, based on review of interim on-treatment efficacy from the two ongoing VBR triple combination studies. The data indicate that the triple combinations do not show a benefit in multiple key viral parameters compared to the dual combinations without VBR in either study.

…As a result of these data, Study 203, an open-label, Phase 2 study evaluating the triple combination of VBR + nucleos(t)ide analogue reverse transcriptase inhibitors (NrtI) + interferon (PEG-IFN-alpha) versus the dual combinations of VBR + NrtI and NrtI + PEG-IFN-alpha, will conclude immediately.

No additional clinical studies of VBR are currently planned. This is hardly a surprise. In #msg-167605073 (from Jan 2022) I said: [ASMB’s] first HBV core inhibitor, VBR (f/k/a ABI-H0731), failed in a 2-drug combination with a nucleoside (#msg-159327881) and is now in various combination trials with external agents (#msg-157913492, #msg-166413748). These trials have a low chance of success (IMO) because VBR is a weak agent on its own, so there would need to be an astonishing degree of synergy for such combinations to provide a functional cure for HBV (the goal that all HBV companies are pursuing). All told, the VBR program looks like an example of Zebra’s Law.

ASMB announces small-molecule IFN-receptor candidate for HBV program:

https://finance.yahoo.com/news/assembly-biosciences-introduce-small-molecule-120000640.html Assembly Biosciences…plans to host a webcast on Tuesday, July 26, 2022 from 1:30-2:30 pm PT/4:30-5:30 pm ET to introduce its new research program advancing a novel, small molecule interferon-alpha receptor (IFNAR) agonist designed to selectively activate the interferon-alpha pathway within the liver and offer the convenience of oral dosing. As far as I know, no other HBV company is pursing this approach. I wonder why the webcast is scheduled for five weeks from now rather than sooner.

Please see #msg-167605073 and #msg-168960516 for related info.

ASMB starts phase-1b trial of ABI-H3733:

https://finance.yahoo.com/news/assembly-biosciences-initiates-phase-1b-120000488.html

See #msg-167605073 for background info.

Izzy Englander likes $ASMB...

https://finance.yahoo.com/news/billionaire-israel-englander-pulls-trigger-133848525.html

ASMB dumps Antios HBV collaboration_following safety problem:

https://www.sec.gov/ix?doc=/Archives/edgar/data/1426800/000156459022021134/asmb-8k_20220518.htm On May 18, 2022, Assembly Biosciences, Inc. (the “Company”) was notified by Antios Therapeutics, Inc. (“Antios”) that ATI-2173, Antios’s investigational proprietary active site polymerase inhibitor nucleotide, has been placed on clinical hold by the U.S. Food and Drug Administration following submission of a safety report involving a patient who received a triple combination of the Company’s lead core inhibitor, vebicorvir, ATI-2173 and a nucleos(t)ide analog reverse transcriptase inhibitor.

Effective May 20, 2022, because of the clinical hold, the Company terminated the Clinical Trial Collaboration Agreement between the Company and Antios. I didn’t think much of ATI-2173 anyhow—see #msg-164648753 and #msg-167129703.

ASMB 3/31/22 cash=$146.5M—1Q22 burn=$28.1M:

https://finance.yahoo.com/news/assembly-biosciences-reports-first-quarter-200500907.html

No CC.

ASMB 4Q21 financials—12/31/21_cash=$174.6M:

https://finance.yahoo.com/news/assembly-biosciences-reports-fourth-quarter-210500365.html

No CC.

Comments on ASMB’s valuation and pipeline:

#msg-167605073

ASMB 2022 newsflow:

https://investor.assemblybio.com/news-releases/news-release-details/assembly-biosciences-outlines-anticipated-2022-pipeline

Note: ASMB nominally has three HBV core inhibitors: i) VBR (f/k/a ABI-H0731), which is in various phase-2 trials using 3-drug regimens, but failed badly in a 2-drug trial with a nuc (#msg-159327881); ii) ABI-H3733 (in phase-1a); and iii) ABI-4334 (preclinical).

A fourth core inhibitor, ABI-H128, was axed due to liver tox (#msg-165734953).

ASMB discontinues HBV core inhibitor, ABI-H2158 due_to_liver_tox:

https://www.globenewswire.com/news-release/2021/09/01/2290389/16259/en/Assembly-Bio-Announces-Decision-to-Discontinue-Clinical-Development-of-ABI-H2158.html

This company can’t seem to get anything right! Please see #msg-162149575, #msg-159327881 for background info.

ASMB 1Q21 results:

https://finance.yahoo.com/news/assembly-biosciences-reports-first-quarter-200500927.html Cash, cash equivalents and marketable securities were $214.9 million as of March 31, 2021, compared to $216.4 million as of December 31, 2020. This result includes $34.1 million of net proceeds from the issuance of common shares under Assembly Bio’s at-the-market (ATM) program. No CC.

ASMB axes ABI-H0731 program:

https://finance.yahoo.com/news/assembly-biosciences-updates-pipeline-strategy-210000963.html Assembly Biosciences…today announced that it is foregoing its plans to initiate Phase 3 registrational studies of vebicorvir (VBR, or ABI-H0731) as a chronic suppressive therapy (CST) to concentrate its research and development efforts on finite and curative HBV therapies.

As part of this focused strategy on finite and curative HBV therapies, Assembly Bio will prioritize its portfolio of potent next generation core inhibitors and combinations of VBR with complementary mechanisms of action, and plans to rapidly advance multiple research programs focused on novel targets and new mechanisms to the clinic. The company evidently agrees with my take on the program spelled out in #msg-159346890.

ASMB axes microbiome program:

https://www.sec.gov/Archives/edgar/data/1426800/000156459020056460/asmb-ex991_33.htm

They tried to sell the program, but there were no buyers.

ASMB seems to be acknowledging that its in-house CpAMs are not good enough:

https://www.globenewswire.com/news-release/2020/11/16/2127221/0/en/Assembly-Biosciences-and-Door-Pharmaceuticals-Sign-Collaboration-and-Option-Agreement-to-Develop-a-Novel-Class-of-HBV-Core-Protein-Modulators.html

* * $ASMB Video Chart 11-06-2020 * *

Link to Video - click here to watch the technical chart video

Good luck! I have no position, FWIW.

Another ticker a week ago TCDA did a similar drop of over 55%. I was gonna buy at $3.90 but didn't. Days later it's back to upper $7's. I grabbed some ASMB

Stock down 68%, much worse than yesterday's AH session.

Is ASMB now a buy? It depends! See #msg-159346890.

ASMB 3Q20 results—9/30/20 cash=$238M:

https://www.globenewswire.com/news-release/2020/11/05/2121483/0/en/Assembly-Biosciences-Reports-Third-Quarter-2020-Financial-Results-and-Business-Update.html

ASMB—(-37%/AH)—suffers_massive_phase-2_failure in HBV:

https://www.globenewswire.com/news-release/2020/11/05/2121468/0/en/Assembly-Biosciences-Provides-Update-on-the-Ongoing-Phase-2-Extension-Study-of-Vebicorvir-in-Patients-with-Chronic-Hepatitis-B-Virus-Infection.html Assembly Biosciences…provided an update on the ongoing open-label Phase 2 extension study (Study 211) of vebicorvir (VBR, or ABI-H0731) in patients with chronic HBV infection. A first of its kind, Study 211 is exploring whether sustained virologic response (SVR) could be achieved after discontinuing therapy in virologically-suppressed patients who had received at least 12-18 months of combination treatment with core inhibitor VBR and a nucleos(t)ide analogue reverse transcriptase inhibitor (NrtI). Study patients who met the treatment stopping criteria discontinued therapy and have been assessed monthly for safety and relapse. The study has not achieved meaningful SVR rates as 39 of 41 patients have now relapsed. I previously posted that ABI-H0731 appeared to have only modest efficacy (#msg-156515976), which is why ASMB has a backup CpAM compound for HBV called ABI-H2158. Today’s failure presumably spells the end of ABI-H0731 as a serious candidate.

Note: ENTA has an HBV CpAM in phase-2 that the CEO says is much more potent than ABI-H0731 (#msg-156787041).

ASMB, ABUS collaborate on phase-2 HBV trial testing triple combination vs double combinations (plural):

https://www.globenewswire.com/news-release/2020/08/27/2084756/0/en/Assembly-Biosciences-and-Arbutus-Biopharma-Announce-Clinical-Collaboration-Agreement-to-Evaluate-the-Combination-of-Core-Inhibitor-ABI-H0731-with-RNAi-Therapeutic-AB-729-in-Patient.html A randomized, multi-center, open-label Phase 2 clinical trial will explore the safety, pharmacokinetics, and antiviral activity of the triple combination of HBV core inhibitor ABI-H0731 [from ASMB], RNAi therapeutic AB-729 [from ABUS] and an NrtI [Vemlidy or Baraclude] compared to the double combinations of ABI-H0731 with an NrtI and AB-729 with an NrtI.

This clinical trial is projected to initiate in the first half of 2021 and enroll approximately 60 virologically-suppressed patients with HBeAg negative or positive chronic HBV infection. Patients will be dosed for 48 weeks, with a 24 week follow-up period. The companies are sharing the cost of the trial, but no other money is changing hands.

Note that ABI-H0731 is not ASMB’s latest-generation core inhibitor (CpAM), and it has shown only modest efficacy as monotherapy—see #msg-156515976 and #msg-152253534.

ASMB 6/30/20 cash=$226.7M—2Q20 burn=$22.4M:

https://www.globenewswire.com/news-release/2020/08/05/2073625/0/en/Assembly-Biosciences-Reports-Second-Quarter-2020-Financial-Results-and-Recent-Highlights.html

No CC.

ASMB—(+10%)—inks deal with BGNE for Greater-China development/commercialization of ASMB’s HBV core inhibitors—$40M up-front cash for ASMB ($500M biobucks):

https://www.globenewswire.com/news-release/2020/07/20/2064219/0/en/Assembly-Biosciences-and-BeiGene-Announce-License-and-Collaboration-Agreement-in-China-for-Assembly-s-Portfolio-of-Three-Clinical-Stage-Core-Inhibitors-for-Chronic-Hepatitis-B-Infe.html

*Includes Taiwan, Hong Kong, Macao.

ASMB starts phase-2 for second-generation HBV CpAM, ABT-H2158:

https://www.globenewswire.com/news-release/2020/06/25/2053349/0/en/Assembly-Biosciences-Initiates-Phase-2-Trial-Evaluating-Second-Generation-Core-Inhibitor-ABI-H2158-for-Chronic-Hepatitis-B-Infection.html

ASMB’s first-generation CpAM, ABI-H0731, has shown only modest efficacy (#msg-152253534).

ASMB 1Q20 results and HBV update…

PR:
https://www.globenewswire.com/news-release/2020/05/07/2029911/0/en/Assembly-Biosciences-Reports-Updates-on-Corporate-Progress-and-First-Quarter-2020-Financial-Results.html

CC slides:
https://investor.assemblybio.com/static-files/3ac91116-5fe8-45ce-b823-43ca9cd148dc